Peregrine begins Nasdaq grace period

Biopharmaceutical firm Peregrine Pharmaceuticals has been notified by Nasdaq that its common stock has failed to maintain a minimum bid price of $1.00 over the last 30 consecutive trading days. The Tustin, CA-based company said it has 180 days, or until February 18, 2003, to regain compliance with Nasdaq SmallCap Market listing requirements by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive trading days.

By AuntMinnie.com staff writers
August 22, 2002

Related Reading

Peregrine closes institutional investment deal, August 14, 2002

Peregrine lands $5.75 million investment, November 19, 2001

Biopharmaceutical firm Peregrine hawks new agents, September 19, 2001

Copyright © 2002 AuntMinnie.com

Page 1 of 436
Next Page